AstraZeneca: new evidence on Farxiga's safety profile.

(CercleFinance.com) - Over the weekend AstraZeneca presented new data underpinning the safety profile of Farxiga, the company's adult type-2 diabetes medication.


In an updated safety analysis, data pooled from 30 Phase IIb/III clinical trials for the drug showed no new safety signals and the incidence of adverse events was generally similar to that in the control groups.

The firm also presented three new outcome analyses examining reductions in cardiovascular events for SGLT-2 inhibitors, including Farxiga in patients with and without cardiovascular disease versus DPP-4 inhibitors.

In short, AstraZeneca thinks that the data that was presented underpins Farxiga's safety and highlights the potential for earlier use of the SGLT-2 inhibitor class, and in broader patient populations than originally understood.

Copyright (c) 2017 CercleFinance.com. All rights reserved.